From achieving the first remissions of ALL and Wilm's tumor
in pediatric patients in the '40s and '50s, to the
development of Gleevec, the first "smart" cancer drug, in
the late '90s, Dana-Farber researchers and clinicians have
been at the forefront of discovery in cancer care and research.
learn more
